TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today reported its results for the three and twelve month periods ended December 31, 2015. Unless otherwise noted, all amounts are in U.S. dollars.
“2015 was a challenging year for Acerus driven primarily by the overall market sector downturn, our U.S. partner’s decision to move away from NATESTO™ and the approval of a generic ESTRACE® in Canada late in the year.
